<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-buprenorphine.xml</id>
  <title>Recalls Watch: Buprenorphine</title>
  <link rel="self" href="https://recalls.watch/feed/substance-buprenorphine.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-10-07T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/99902/</id>
    <title>Par Health USA, LLC: Buprenorphine Hydrochloride</title>
    <link href="https://recalls.watch/recall/fda/99902/"/>
    <updated>2026-10-07T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Crystallization</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/99674/</id>
    <title>American Health Packaging: Buprenorphine Sublingual Tablets</title>
    <link href="https://recalls.watch/recall/fda/99674/"/>
    <updated>2026-09-09T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Labeling: Label Mix-up</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/99237/</id>
    <title>Par Health USA, LLC: Buprenorphine HCl</title>
    <link href="https://recalls.watch/recall/fda/99237/"/>
    <updated>2026-06-24T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Crystallization; identified as Buprenorphine free base</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/98610/</id>
    <title>ENDO USA, Inc.: Buprenorphine Hydrochloride</title>
    <link href="https://recalls.watch/recall/fda/98610/"/>
    <updated>2026-05-20T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Crystallization; identified as Buprenorphine free base</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/94681/</id>
    <title>Pfizer Inc.: Buprenorphine Hydrochloride Injection and 1 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=94681"/>
    <updated>2024-07-03T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility-The potential for incomplete crimp seals.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/65360/</id>
    <title>Lowlite Investments, Inc. D/B/A Olympia Pharmacy: Acetyl-D-Glucosamine w/Chondroitin 200 mg/ml and 104 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=65360"/>
    <updated>2013-07-17T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes</summary>
  </entry>
</feed>
